The fifth edition of IBS Days delved into the latest developments in IBS research and clinical management. This article aims to explore causes that can be misdiagnosed as IBS and non-pharmacological strategies targeting gut barrier and gut microbiome dysfunction.
Species-level, food-specific associations predicted in a cohort of 10,068 people may guide personalized nutrition
6 Jul 2026by Andreu Prados
While diet is a major determinant of the human gut microbiome, little is known about diet-microbiome associations at species-level resolution. New findings from the Human Phenotype Project found species-level, food-specific associations validated at population scale that might guide personalized nutrition.
One in four adults experience digestive symptoms that impact quality of life
15 Jun 2026by Andreu Prados
Digestive symptoms with an impact on quality of life (QoL) affect one in four adults in the general population worldwide who do not qualify for a diagnosis of a Disorder of Gut-Brain Interaction (DGBI). Recent research suggests this ‘sub-diagnostic’ group demands additional investigation and might benefit from targeted interventions, including dietary interventions.
From regulation to opportunity: shaping the future of microbiome-based therapies in Europe
8 Jun 2026by Konstantina Zafeiropoulou
The European regulatory landscape for microbiome-based therapies is rapidly evolving. New frameworks like the SoHO Regulation aim to harmonize safety, quality, and access across countries. This article explores the current challenges, opportunities, and expert perspectives shaping the field.
Rethinking diet and the gut microbiome in IBD: from risk to treatment and beyond
28 May 2026by GMFH Editing Team
The role of diet and the gut microbiome in inflammatory bowel disease (IBD) continues to evolve, from shaping disease risk to supporting treatment strategies. In this interview with Richard Hansen and Chen Sarbagili, we discuss key misconceptions, emerging evidence, and what the future may hold for microbiome-based approaches in IBD.
GMFH World Summit 2026: Diet and other ways to manipulate the gut microbiome in clinical practice
14 May 2026by Andreu Prados
With nearly 240 participants from 27 countries, the 14th edition of GMFH World Summit covered basic, translational and clinical science supporting the integration of microbiome-targeted interventions into preventive and therapeutic strategies for gastrointestinal disorders, cardiometabolic diseases, and cancer.
For patients with celiac disease on a gluten-free diet, fiber may work best with the right gut microbes
27 Apr 2026by Heather Galipeau, Mark Wulczynski
A new study reveals that the benefits of dietary fiber in celiac disease depend not only on intake, but also on the presence of specific gut microbes capable of metabolizing it. These findings highlight the need for more personalized dietary strategies beyond the gluten-free diet.
A global consensus establishes a basis for measuring and improving gut health
6 Apr 2026by Andreu Prados
While “gut health” is becoming a popular term, mainly in media and marketing claims but also in the clinical context, researchers have not yet nailed down a definition. Now, a global group of 13 scientists and clinicians updates a consensus definition of gut health and implications from bench to bedside.
The management of disorders of gut-brain interaction based on their causes was a central topic addressed at NeuroGASTRO 2025. In this video interview, Dr. Javier Santos delves into the role of mast cells in postprandial symptoms and the present and future of microbiome-based interventions for bowel disorders.
Intermittent fasting and eating rhythmicity: what we know about their impact on metabolic and gut health
2 Mar 2026by Manon Oliero
Much of nutrition science has centred on what we put on our plate, yet when we choose to eat may be just as consequential. Intermittent fasting (IF) has gained attention as a strategy that may support metabolic health while also reshaping microbial rhythms, gut hormone secretion, and intestinal function. The growing interest surrounding this approach raises an essential question for clinical practice: does IF truly translate into measurable benefits?
